Oasmia Rises on FDA Dog Cancer Drug Designation: Stockholm Mover

Oasmia Pharmaceutical AB, a Swedish maker of veterinary drugs, rose the most in over three years in Stockholm after the company said it had received Minor Use designation in the U.S. for its Doxophos Dog cancer treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.